TAK-861 is a medication being studied for its potential to treat narcolepsy with cataplexy, also known as Narcolepsy Type 1. This condition is characterized by excessive daytime sleepiness (EDS) and sudden muscle weakness triggered by strong emotions. The trial aims to evaluate how well TAK-861 can reduce daytime sleepiness, as measured by a specific scale called the Epworth Sleepiness Scale (ESS). The study is designed to ensure that neither the participants nor the researchers know who is receiving the actual medication, which helps to provide unbiased results.

Narcolepsy with Cataplexy (Narcolepsy Type 1) – This is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with this condition often experience cataplexy, which is a sudden loss of muscle tone triggered by strong emotions such as laughter or surprise. The disorder disrupts the normal sleep-wake cycle, leading to fragmented nighttime sleep and excessive daytime sleepiness. Individuals may also experience sleep paralysis and hallucinations as they fall asleep or wake up. The progression of symptoms can vary, but they often begin in childhood or adolescence and persist throughout life. The condition is considered a rare disease and can significantly impact daily activities and quality of life.